Humacyte, Inc.
$0.69
▲
8.53%
2026-04-21 07:23:01
www.humacyte.com
NMS: HUMA
Explore Humacyte, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$157.68 M
Current Price
$0.69
52W High / Low
$2.93 / $0.55
Stock P/E
—
Book Value
$0.02
Dividend Yield
—
ROCE
-110.35%
ROE
164.78%
Face Value
—
EPS
$-0.26
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
184
Beta
2.1
Debt / Equity
2,101.83
Current Ratio
3.69
Quick Ratio
2.95
Forward P/E
-3.52
Price / Sales
70.31
Enterprise Value
$158.14 M
EV / EBITDA
-1.58
EV / Revenue
77.6
Rating
Buy
Target Price
$5.1
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Codexis, Inc. | $2.62 | — | $235.35 M | — | -31.3% | -74.88% | $3.87 / $0.96 | $0.56 |
| 2. | Cullinan Therapeutics, Inc. | $14.52 | — | $911.52 M | — | -58.85% | -44.02% | $16.74 / $5.68 | $6.79 |
| 3. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 4. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
| 5. | Invivyd, Inc. | $1.68 | — | $492.08 M | — | -22.89% | -33.97% | $3.07 / $0.46 | $0.86 |
| 6. | Immatics N.V. | $11.25 | — | $1.51 B | — | -35.05% | -37.1% | $12.41 / $3.94 | $4.18 |
| 7. | Hyperion DeFi, Inc. | $4.28 | — | $48.76 M | — | -38.69% | -3.24% | $17.18 / $1.02 | $4.73 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.47 M | 0.75 M | 0.3 M | 0.52 M | 0 M | — |
| Operating Profit | -30.84 M | -24.39 M | -29.73 M | -23.18 M | -28.09 M | — |
| Net Profit | -24.8 M | -17.51 M | -37.66 M | 39.14 M | -20.94 M | — |
| EPS in Rs | -0.11 | -0.08 | -0.17 | 0.18 | -0.09 | -0.33 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.04 M | 0 M | 0 M | 0 M |
| Operating Profit | -108.14 M | -114.4 M | -100.05 M | -84.58 M |
| Net Profit | -40.83 M | -148.7 M | -110.78 M | -11.96 M |
| EPS in Rs | -0.18 | -0.67 | -0.5 | -0.05 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 116.37 M | 137.87 M | 128.22 M | 204.3 M |
| Total Liabilities | 113.26 M | 190.54 M | 114.68 M | 87.37 M |
| Equity | 3.11 M | -52.67 M | 13.55 M | 116.93 M |
| Current Assets | 67.8 M | 47.86 M | 83.28 M | 154.21 M |
| Current Liabilities | 18.37 M | 19.95 M | 18.44 M | 19.58 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -105.04 M | -98.12 M | -73.31 M | -71.13 M |
| Investing CF | -0.88 M | -1.57 M | -0.17 M | 4.84 M |
| Financing CF | 61.49 M | 114.18 M | 4.51 M | -1.45 M |
| Free CF | -105.93 M | -99.69 M | -75.58 M | -72.18 M |
| Capex | -0.88 M | -1.57 M | -2.28 M | -1.05 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -34.24% | -825.83% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.